Osteosarcoma is the most common primary bone tumor in dogs. Despite aggressive treatment with surgery and chemotherapy, most dogs die of metastatic disease that is resistant to conventional chemotherapy. Metronomic chemotherapy entails very small doses of chemotherapy that are given daily or every other day and help to deter the growth of new blood vessels needed to nourish cancer as it grows. Side effects associated with metronomic chemotherapy tend to be milder and less frequent than those seen with standard chemotherapy. The goal of this study is to evaluate for an increased disease free interval in dogs treated with standard of care surgery and chemotherapy followed with maintenance metronomic or low dose chemotherapy.
Dogs with osteosarcoma that have completed a standard course of chemotherapy after limb amputation.
Dogs with a life expectancy of less than 1 month or who have lower urinary tract disease are ineligible to participate in this study.
This study is not funded; so pet owners are responsible for all costs associated with this treatment.
Kelly Reed, Oncology Liaison
Phone: (508) 887-4682